Latest News on NVAX

Financial News Based On Company


Advertisement
Advertisement

Novavax ( NVAX ) Exceeds Market Returns: Some Facts to Consider

https://www.zacks.com/stock/news/2759843/novavax-nvax-exceeds-market-returns-some-facts-to-consider
The latest trading day saw Novavax (NVAX) settling at $8.67, representing a +1.17% change from its previous close.

Here's Why Novavax ( NVAX ) is a Strong Momentum Stock

https://www.zacks.com/stock/news/2757655/heres-why-novavax-nvax-is-a-strong-momentum-stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here is What to Know Beyond Why Novavax, Inc. ( NVAX ) is a Trending Stock

https://www.zacks.com/stock/news/2756865/here-is-what-to-know-beyond-why-novavax-inc-nvax-is-a-trending-stock
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Novavax ( NVAX ) Declines More Than Market: Some Information for Investors

https://www.zacks.com/stock/news/2755995/novavax-nvax-declines-more-than-market-some-information-for-investors
Novavax (NVAX) concluded the recent trading session at $8.68, signifying a -2.2% move from its prior day's close.

Elizabeth Warren Says Measles Can Hit Record Highs, Slams RFK Jr.'s CDC Panel For Delaying Vaccine: 'How Does That Keep Our Kids Safe?' - Dynavax Technologies ( NASDAQ:DVAX ) , GSK ( NYSE:GSK )

https://www.benzinga.com/news/health-care/25/09/47754844/elizabeth-warren-says-measles-can-hit-record-highs-slams-rfk-jr-s-cdc-panel-for-delaying-vaccine
Sen. Elizabeth Warren ( D-Mass. ) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps, rubella, and varicella or MMRV vaccine for children under 4 years old.
Advertisement

Here's Why Novavax ( NVAX ) Fell More Than Broader Market

https://www.zacks.com/stock/news/2753065/heres-why-novavax-nvax-fell-more-than-broader-market
Novavax (NVAX) closed at $8.39 in the latest trading session, marking a -1.99% move from the prior day.

MRNA Stock Rises as Updated COVID-19 Jab Shows Strong Immune Response

https://www.zacks.com/stock/news/2752813/mrna-stock-rises-as-updated-covid-19-jab-shows-strong-immune-response
Moderna jumps after its updated formulation of Spikevax shows an over 8-fold increase in neutralizing antibodies against the LP.8.1 COVID-19 variant in phase IV study.

Robert Kennedy Jr. Packs CDC Panel With Vaccine Skeptics Ahead of Key Vote On COVID-19 Shots - Merck & Co ( NYSE:MRK ) , GSK ( NYSE:GSK )

https://www.benzinga.com/news/health-care/25/09/47683446/robert-kennedy-jr-packs-cdc-panel-with-vaccine-skeptics-ahead-of-key-vote-on-covid-19-shots
Health and Human Services Secretary Robert F. Kennedy Jr. has added five new members to the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, just days before it reconvenes to vote on COVID-19 shots and other routine pediatric vaccine recommendations.

COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths

https://www.zacks.com/stock/news/2751283/covid-19-vaccine-stocks-fall-on-reports-linking-shots-to-child-deaths
MRNA, BNTX, PFE and NVAX stocks fall as health officials reportedly plan to link COVID-19 vaccines to child deaths ahead of a key CDC meeting.

Pfizer, Moderna shares fall on report that Trump officials will link child deaths to Covid shots

https://www.cnbc.com/2025/09/12/pfizer-moderna-shares-fall-on-trump-child-covid-shot-report.html
The report says officials plan to include the claim in a presentation next week to a key vaccine panel that advises the CDC on shot access and coverage.
Advertisement

FDA Moves To Publicize Data On Pregnant Women's Covid Vaccine Side Effects - Novavax ( NASDAQ:NVAX ) , Moderna ( NASDAQ:MRNA ) , Pfizer ( NYSE:PFE )

https://www.benzinga.com/news/fda/25/09/47604090/fda-moves-to-publicize-data-on-pregnant-womens-covid-vaccine-side-effects
FDA seeks to lift privacy rules on Covid vaccine data for pregnant women to reveal more potential side effects. Pfizer, Moderna and Novavax defended their vaccines after Trump's transparency call, citing safety data for pregnant women. Get the data-driven signals to profit from September ...

Novavax, Inc. ( NVAX ) is Attracting Investor Attention: Here is What You Should Know

https://www.zacks.com/stock/news/2749210/novavax-inc-nvax-is-attracting-investor-attention-here-is-what-you-should-know
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Florida Chooses 'Medical Freedom' As State Plans To End Vaccine Mandates, Even For Schools: Experts Warn Of 'Major Disaster' - Merck & Co ( NYSE:MRK ) , GSK ( NYSE:GSK )

https://www.benzinga.com/news/health-care/25/09/47490782/florida-chooses-medical-freedom-as-state-plans-to-end-vaccine-mandates-even-for-schools-experts-
Florida plans to end all statewide vaccine mandates, even those required for school attendance, framing the move as a defense of individual liberties, which has since received pushback from public health experts.

Bernie Sanders Demands Health Secretary RFK Jr.'s Resignation As CDC Leadership Crisis Deepens - Merck & Co ( NYSE:MRK ) , GSK ( NYSE:GSK )

https://www.benzinga.com/news/politics/25/08/47431282/bernie-sanders-demands-health-secretary-rfk-jr-s-resignation-as-cdc-leadership-crisis-deepens
Senator Bernie Sanders ( I-VT ) called for Health and Human Services Secretary Robert F. Kennedy Jr.'s resignation on Saturday, citing Kennedy's "dangerous policies" that are "endangering the health of the American people."

Boyd Gaming and Shoe Carnival have been highlighted as Zacks Bull and Bear of the Day

https://www.zacks.com/stock/news/2745125/boyd-gaming-and-shoe-carnival-have-been-highlighted-as-zacks-bull-and-bear-of-the-day
Boyd Gaming surges on strong earnings and growth plans, while Shoe Carnival struggles with sliding sales and weaker momentum.
Advertisement

FDA Approves Updated COVID-19 Vaccines but With Restrictions

https://www.zacks.com/stock/news/2744393/fda-approves-updated-covid-19-vaccines-but-with-restrictions
FDA clears updated COVID-19 vaccines from Pfizer, Moderna and Novavax but limits access to older adults and high-risk groups.

Why Novavax ( NVAX ) is a Top Momentum Stock for the Long-Term

https://www.zacks.com/stock/news/2744197/why-novavax-nvax-is-a-top-momentum-stock-for-the-long-term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

RFK Jr. Rescinds Emergency Authorizations For COVID-19 Vaccines - Novavax ( NASDAQ:NVAX ) , Moderna ( NASDAQ:MRNA ) , Pfizer ( NYSE:PFE ) , BioNTech ( NASDAQ:BNTX )

https://www.benzinga.com/news/fda/25/08/47368644/rfk-jr-rescinds-emergency-authorizations-for-covid-19-vaccines
FDA approves updated Pfizer, Moderna, and Novavax Covid vaccines for high-risk individuals. Pfizer-BioNTech Covid vaccine doses exceed 5 billion distributed globally. The market is reacting to NVIDIA's earnings. Learn how to time your next trade here → Health and Human Services Secretary Robert ...

FDA ends broad Covid vaccine authorization as RFK Jr. limits access to immunizations

https://www.cnbc.com/2025/08/27/fda-covid-vaccine-authorization--rfk.html
It's unclear how easily patients without high risk factors will be able to get a Covid shot, and whether insurance plans will still cover them.

Novavax, Inc. ( NVAX ) Is a Trending Stock: Facts to Know Before Betting on It

https://www.zacks.com/stock/news/2743313/novavax-inc-nvax-is-a-trending-stock-facts-to-know-before-betting-on-it
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Advertisement

Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months' - Moderna ( NASDAQ:MRNA ) , BioNTech ( NASDAQ:BNTX )

https://www.benzinga.com/markets/large-cap/25/08/47316871/trump-administration-plans-to-pull-covid-19-vaccines-off-market-within-months
RFK Jr.'s adviser says COVID-19 vaccines could be pulled from the U.S. market within months. MIT professor critical of mRNA shots named to lead federal vaccine task force. See the seasonal trading strategy that's beating the S&P 500 by 6X this year. Details here →

What the Options Market Tells Us About Novavax - Novavax ( NASDAQ:NVAX )

https://www.benzinga.com/insights/options/25/08/47265417/what-the-options-market-tells-us-about-novavax
Investors with a lot of money to spend have taken a bearish stance on Novavax NVAX. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.

Novavax Shares Are Trading Higher Thursday: What's Going On? - Novavax ( NASDAQ:NVAX )

https://www.benzinga.com/trading-ideas/movers/25/08/47263473/novavax-shares-are-trading-higher-thursday-whats-going-on
Novavax issues $225 million of 2031 convertible notes, including $175.3 million exchanged for 2027 notes and $49.7 million in new funding. The new notes convert at $11.14 per share, a 27.5% premium to the company's last closing price.

La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Celldex Therapeutics ( NASDAQ:CLDX ) , Alcon ( NYSE:ALC )

https://www.benzinga.com/trading-ideas/movers/25/08/47231889/la-z-boy-posts-downbeat-q1-results-joins-james-hardie-industries-alcon-and-other-big-stocks-
U.S. stock futures were slightly lower this morning, with the S&P 500 futures falling around 0.1% on Wednesday. Shares of La-Z-Boy Incorporated LZB fell sharply in pre-market trading as the company reported weaker-than-expected financial results for the first quarter of fiscal 2026.

Investors Heavily Search Novavax, Inc. ( NVAX ) : Here is What You Need to Know

https://www.zacks.com/stock/news/2706921/investors-heavily-search-novavax-inc-nvax-here-is-what-you-need-to-know
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Advertisement

FDA may pull authorization of Pfizer's Covid vaccine for children under 5

https://www.cnbc.com/2025/08/12/fda-may-pull-authorization-of-pfizer-covid-shot-for-children-under-5.html
The potential move to rescind authorization of Pfizer's vaccine could leave some kids in the U.S. with no available shots against Covid.

CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency - Moderna ( NASDAQ:MRNA ) , BioNTech ( NASDAQ:BNTX )

https://www.benzinga.com/news/health-care/25/08/47069191/cdc-shooting-linked-to-suspects-covid-19-vaccine-beliefs-former-staff-blame-rfk-jr-hostility-tow
CDC shooter's writings revealed anti-vaccine beliefs and distrust of COVID-19 shots. The NIH chief says that mRNA vaccines lack viability due to public distrust. The next 100%+ earnings move could hit this month. See how to find it live on Wednesday → A group of former U.S.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

https://www.zacks.com/stock/news/2702301/are-you-a-momentum-investor-this-1-stock-could-be-the-perfect-pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply - Moderna ( NASDAQ:MRNA ) , Pfizer ( NYSE:PFE )

https://www.benzinga.com/news/fda/25/08/47039696/fda-may-not-renew-pfizers-authorization-for-covid-shots-in-younger-children-moderna-prepares-to-boost-su
Only 5.6% of children aged 6 months to 4 years old are vaccinated against COVID-19, CDC says. The FDA may not renew Pfizer's pediatric COVID-19 vaccine authorization for the 2025 season. This simple system has nailed 1,000+ post-earnings winners. Get in before Q3 trades take off →

Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction - Cabaletta Bio ( NASDAQ:CABA ) , Moderna ( NASDAQ:MRNA )

https://www.benzinga.com/news/fda/25/08/47028953/vinay-prasads-comeback-to-fda-sparks-debate-over-regulatory-direction
Vinay Prasad returns as FDA's CBER head days after resigning amid Sarepta drug controversy. Analysts see a possible softer stance on rare disease therapies under Prasad. Get ahead of next week's CPI & PPI with Chris Capre's live trading strategy session this Sunday. Register Now →
Advertisement

Baculovirus Expression System Market Poised for Significant Growth, Estimate to Hit USD 781.8 Million by 2032 | Coherent Market Insights

https://www.benzinga.com/pressreleases/25/08/g46999209/baculovirus-expression-system-market-poised-for-significant-growth-estimate-to-hit-usd-781-8-milli
Burlingame, CA, Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- The global Baculovirus Expression System Market is estimated to be valued at USD 436.0 Mn in 2025 and is expected to reach USD 781.8 Mn in 2032, exhibiting a compound annual growth rate ( CAGR ) of 8.7% from 2025 to 2032.

NVAX Stock Gains on Q2 Earnings & Sales Beat, Ups '25 Sales View

https://www.zacks.com/stock/news/2679465/nvax-stock-gains-on-q2-earnings-sales-beat-ups-25-sales-view
Novavax tops Q2 estimates and lifts 2025 sales forecast as Sanofi takes over global rollout of its COVID vaccine.

Novavax ( NVAX ) Profit Jumps on Milestone

https://www.fool.com/data-news/2025/08/06/novavax-nvax-profit-jumps-on-milestone/
Novavax ( NASDAQ:NVAX ) , known for its protein-based vaccine technology, released its second quarter fiscal 2025 results on August 6, 2025. The standout news was a return to profitability on a GAAP basis, driven by significant partnership milestone payments, most notably a $175 million payment ...

Why Is Novavax Stock Soaring Wednesday? - Novavax ( NASDAQ:NVAX )

https://www.benzinga.com/markets/earnings/25/08/46904843/novavax-ups-outlook-eyes-stronger-nuvaxovid-sales
Q2 sales of $239 million beat the consensus of $156.29 million; EPS of $0.62 vs est. loss of $0.05. FY25 guidance raised to $1 billion-$1.05 billion from $975 million-$1.025 billion; Wall Street est. was $1.039 billion. The market's back, and these 3 income stocks are thriving. See them here→

Novavax ( NVAX ) Q2 Earnings and Revenues Top Estimates

https://www.zacks.com/stock/news/2672854/novavax-nvax-q2-earnings-and-revenues-top-estimates
Novavax (NVAX) delivered earnings and revenue surprises of +985.71% and +102.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Advertisement

Novavax Stock Dips As Moderna's Woes Weigh On Vaccine Sector - Novavax ( NASDAQ:NVAX )

https://www.benzinga.com/trading-ideas/movers/25/08/46799525/novavax-stock-dips-as-modernas-woes-weigh-on-vaccine-sector
Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine makers after rival Moderna reported disappointing Q2 results. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.

Novavax ( NVAX ) Sees a More Significant Dip Than Broader Market: Some Facts to Know

https://www.zacks.com/stock/news/2640592/novavax-nvax-sees-a-more-significant-dip-than-broader-market-some-facts-to-know
In the most recent trading session, Novavax (NVAX) closed at $6.85, indicating a -2.28% shift from the previous trading day.

Here is What to Know Beyond Why Novavax, Inc. ( NVAX ) is a Trending Stock

https://www.zacks.com/stock/news/2628481/here-is-what-to-know-beyond-why-novavax-inc-nvax-is-a-trending-stock
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Novavax ( NVAX ) Stock Slides as Market Rises: Facts to Know Before You Trade

https://www.zacks.com/stock/news/2614330/novavax-nvax-stock-slides-as-market-rises-facts-to-know-before-you-trade
Novavax (NVAX) reached $7.64 at the closing of the latest trading day, reflecting a -2.55% change compared to its last close.

Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates - Novavax ( NASDAQ:NVAX )

https://www.benzinga.com/news/health-care/25/07/46605800/novavax-shares-promising-results-for-bird-flu-vaccine-tested-in-primates
Novavax's H5N1 vaccine showed a protective antibody response after just one dose in primates. Two-dose regimens boosted immunity, with data suggesting potential protection against future virus variants. A new wave of value and momentum stocks could be setting up for major moves-and Tim Melvin ...
Advertisement

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

https://www.zacks.com/stock/news/2585450/why-this-1-momentum-stock-could-be-a-great-addition-to-your-portfolio
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Novavax ( NVAX ) Rises Higher Than Market: Key Facts

https://www.zacks.com/stock/news/2580818/novavax-nvax-rises-higher-than-market-key-facts
In the closing of the recent trading day, Novavax (NVAX) stood at $6.97, denoting a +1.9% move from the preceding trading day.

Is Trending Stock Novavax, Inc. ( NVAX ) a Buy Now?

https://www.zacks.com/stock/news/2579527/is-trending-stock-novavax-inc-nvax-a-buy-now
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

2 Beaten-Down Stocks That Haven't Hit Rock Bottom Yet

https://www.fool.com/investing/2025/07/11/2-beaten-down-stocks-that-havent-hit-rock-bottom/
Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive aren't actually so. You should be careful to avoid catching falling knives.Let's consider two stocks that have ...

FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months - Moderna ( NASDAQ:MRNA )

https://www.benzinga.com/news/fda/25/07/46351929/fda-grants-complete-approval-to-modernas-covid-19-vaccine-for-children-as-young-as-6-months
The FDA fully approves Moderna's Spikevax for children six months to 11 years at high risk of COVID-19. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On The U.S.
Advertisement

Medical Groups Sue RFK Jr. For Assault On Science Over Unlawful COVID-19 Vaccine Rollbacks - Novavax ( NASDAQ:NVAX ) , Moderna ( NASDAQ:MRNA )

https://www.benzinga.com/news/health-care/25/07/46303191/medical-groups-sue-rfk-jr-for-assault-on-science-over-unlawful-covid-19-vaccine-rollbacks
17 CDC vaccine advisers were dismissed and replaced with anti-vaccine voices, lawsuit claims. Groups seek injunction to reverse COVID-19 vaccine rollback for kids, pregnant women. Get daily-updated rankings across momentum, growth, value, trends, and quality to spot the strongest stocks in any ...

Novavax ( NVAX ) Dips More Than Broader Market: What You Should Know

https://www.zacks.com/stock/news/2566402/novavax-nvax-dips-more-than-broader-market-what-you-should-know
Novavax (NVAX) closed at $6.61 in the latest trading session, marking a -2.79% move from the prior day.

RFK Jr. Influence Evident As Vaccine Chief Overrules Scientists, Limits COVID-19 Vaccine Approval - Novavax ( NASDAQ:NVAX ) , Moderna ( NASDAQ:MRNA ) , Pfizer ( NYSE:PFE )

https://www.benzinga.com/news/health-care/25/07/46250723/rfk-jr-influence-evident-as-vaccine-chief-overrules-scientists-limits-covid-19-vaccine-approval
FDA chief Prasad overruled staff to limit COVID shots to seniors, high-risk groups. Moderna must study myocarditis risk further to keep approval for its updated vaccine. From tariffs to inflation, macro risks are rising-Matt Maley reveals how he's trading it all, live this Wednesday July 9 at 6 ...

Is Most-Watched Stock Novavax, Inc. ( NVAX ) Worth Betting on Now?

https://www.zacks.com/stock/news/2559348/is-most-watched-stock-novavax-inc-nvax-worth-betting-on-now
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Ginkgo Bioworks ( DNA ) Soars 18.9%: Is Further Upside Left in the Stock?

https://www.zacks.com/stock/news/2559125/ginkgo-bioworks-dna-soars-189-is-further-upside-left-in-the-stock
Ginkgo Bioworks (DNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement